The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market size was valued at USD 7.23 billion in 2020 and is expected to reach USD 16.1 Billion by 2027. It is expected to exhibit a CAGR of 12.1% during the forecast period. Increasing adoption of novel therapeutics, rising geriatric population, and the emergence of biologics are likely to be some of the primary growth stimulants for the market during the same period.
Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare blood disease of stem cells of the bone marrow that are genetically characterized by somatic mutation in the A (PIG-A) gene of phosphatidylinositol glycan. PNH happens mainly in the early 30s. About 10 percent of patients show signs of PNH at or before the age of 21. In the U.S., it is estimated that about 1 to 5 individuals per million people suffer from PNH. This is substantially lower than bone marrow aplasia incidence levels. PNH sometimes goes unrecognized; diagnostic delay can vary from one year to over 10 years.
These firms are focused on developing effective PNH treatment for which the firms collaborate with research institutes and labs.
Alexion is currently market leader and is estimated to maintain its market position over the coming years, supported by continued strong Soliris uptake and potential ALXN1210 approval over the projected period.
Late-stage pipeline products such as Akari'sCoversin and Apellis' APL2 have shown favourable clinical profiles and promise to gain significant share after their approvals. The industry is expected to see the introduction of the Amgen (ABP959), CinnaGen, and ISU Abxis biosimilar edition of Soliris.
The global market for PNH treatment can be segmented by type of treatment and end-user. Based on the type of treatment, the market for PNH treatment can be divided into Stem cell transplantation, Blood transfusion, and Medication. The PNH care market can be divided into hospitals, pharmaceutical & biotech firms, clinics, academic & research institutes and others, based on end-user. During the forecast period, drugs are expected to show the highest growth followed by stem cell transplants and blood transfusions.
Report : Paroxysmal Nocturnal Haemoglobinuria (PNH) Treatment Market - By Treatment (Stem cell transplantation, Blood transfusion, Medication) By End User (Hospitals, Clinics, Pharmaceutical and biotech companies, Academic & research institutes, Others) By Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa) - Industry Analysis, Opportunity and Forecast 2020 To 2027